Discover why your peers are part of
this innovative development network
“As leaders in the microbiome field with the goal to develop both safe and efficacious LBP drugs to meet the unmet needs of patients; we are all simultaneously facing our challenges. The most logical way to bring LBPs to market at an efficient pace is to share our experiences and knowledge whilst maintaining our Intellectual Property, that will accelerate benefits to the patient. And this is the opportunity I see that the Searchlight Network will provide.”
Samantha Coulson, Head of Clinical Research, Servatus Biopharmaceuticals
“We can support one another in making meaningful progress by exchanging knowledge and offering guidance based on our own experiences. Being part of this Microbiome Drug Development Searchlight network means that we are more than willing to work collectively in this exciting and challenging fast-growing field.”
Karine Roget, Chief Scientific Officer, Nexbiome
“My view is that the microbiome therapeutics sector is at a critical juncture as first-generation donor derived programs move into the clinical and cell bank derived consortia and single strain products move further down clinic translation. To help the sector address these challenges we require a central forum that can focus on the technical aspects of regulatory, CMC and clinical development. This searchlight network has the potential to be that essential forum for the microbiome industry”
Trent Munro, Senior Vice President of Therapeutics, Microba
“I believe cross-discipline scientific, manufacturing, and regulatory expertise will be essential the next generation of microbiome-based therapies, and this network provides an important opportunity to build a community to address these areas.”
Laura Cox, Assistant Professor, Assistant Professor in the Department of Neurology at the Ann Romney Center for Neurologic Diseases at Harvard Medical School and BWH Hospital
“It's important in a new field that companies, even though they are intrinsically competitors at some levels, also try to share experiences and learn from each other”
Sam Posseimers, CEO, MRM Health
“I joined this network because I believe that microbiome therapeutics will be transformational for human health. I want to find creative ways to accelerate development in this modality by collaborating with my peers across the industry on our common challenges.”
Sonia Timberlake, Independent Consultant and former SVP at Finch Therapeutics
“It is a good time for a network like this to really gain momentum and try to succeed as a whole industry.”
Hyun Kim, VP and Head of Clinical Operations, AOBiome
Accelerate your Microbiome Drug Development success
Be inspired by forward-thinking leaders. Grow beyond your perceived
limits. Connect with members. Redefine and realize your business goals
with Searchlight by Hanson Wade.